C3i, a Centre of Excellence for Commercialisation and Research, accelerates access to innovative therapies in immuno-oncology and regenerative medicine for patients.
Operating in Montreal, Canada, C3i offers an integrated structure for the development, translation and commercialisation of these ground breaking therapies.
Acting as a “one-stop-shop” solution for Cell and Gene Therapy, C3i combines five interacting units:
– GMP Manufacturing Unit for Regenerative Medicine and Cancer Immunotherapy
– Biomarker-Diagnostics Unit
– Clinical Research Unit
– CRO Unit
– Innovation and Commercialization Unit